- Home
- MOBX vs ANL Comparison
MOBX vs ANL Comparison
Compare MOBX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MOBX | ANL |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MOBX | ANL |
|---|---|---|
| Price | $0.54 | $1.01 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 13.6K |
| Earning Date | 12-19-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,984,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 180.13 | N/A |
| 52 Week Low | $0.40 | $1.00 |
| 52 Week High | $2.47 | $2.99 |
Technical Indicators
Market Signals| Indicator | MOBX | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 23.81 |
| Support Level | $0.43 | $1.32 |
| Resistance Level | $0.50 | $1.59 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 80.88 | 1.69 |
Price Performance
Historical ComparisonAbout MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.